May 18, 2016

Hypoglycemia From Residual Insulin – Ever Heard of It?

New technology from Monarch Medical Technologies statistically eliminates severe hypoglycemia in hospital glucose management.
September 1, 2015

Monarch Medical Technologies Shifts Market with Safest Insulin Therapy Treatment

Monarch has achieved a 30 percent growth in total installed sites, an increase in go‐lives by seven times, a five‐fold increase in sales, a second FDA 510(k) clearance for EndoTool SubQ, and a 40 percent increase in new personnel.
June 3, 2015

Monarch Medical Technologies Receives FDA 510(k) Clearance for EndoTool SubQ

EndoTool SubQ utilizes clinically-proven and patent-pending model predictive control technology to determine the safest patient-specific basal/bolus and correction subcutaneous insulin dose recommendations.
September 23, 2014

Monarch Medical Technologies Establishes Medical Advisory Board With Experts from Across Healthcare Continuum

The board, which will serve to counsel the company on strategic areas of interest, includes members from both the U.S. and abroad and leverages both healthcare and analytics experts.
April 28, 2014

Monarch Medical Technologies Launches New EndoTool IV to Further Enhance Patient-Specific Glycemic Control in Hospitals

Next generation glucose management solution offers several new features to aid healthcare professionals in addressing the most complex cases.
September 10, 2013

Monarch Medical Technologies Achieves ISO 13485 Certification

The international quality standard certifies Monarch’s ability to offer medical devices and related services that consistently meet applicable customer needs and regulatory requirements.
June 24, 2013

Study: EndoTool Glucose Management System Boosts Vidant Medical Center’s Surgical Care Improvement Project Scores, Doubles Cost Savings in Hospital-Acquired Conditions

Vidant Medical Center, the flagship hospital for Vidant Health and teaching hospital for Brody School of Medicine at East Carolina University, has demonstrated that implementing EndoTool resulted in controlled and sustained improvements in blood sugar levels among patients.
May 20, 2013

Private Investment Firm Eigen Capital Unveils Monarch Medical Technologies, New Corporate Entity Behind Market-Leading EndoTool Solution

The Monarch name was selected to reflect the company’s mission of transforming the way drugs of concern are dosed and processes of concern are handled in a hospital setting.